{"analyses":[{"groupDescription":"Null hypothesis: Two-year survival rate \\<= 64%; Alternative hypothesis: Two-year survival rate \\> 64%. The fixed survival rate for comparison comes from Radiation Therapy Oncology Group (RTOG) trial 9310. (RTOG 9310 does not fall within ClinicalTrials.gov registration/reporting requirements.)","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.006","statisticalMethod":"One-sample z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.1","upperLimit":"91.5","value":"80.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. (Please note that this outcome measure is considered the primary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. )","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase I: Temozolomide 100mg and Phase II: Temozolomide 100 mg","id":"OG000","title":"Combined Temozolomide 100mg Arms"}],"paramType":"NUMBER","populationDescription":"Eligible patients on Temozolomide 100 mg arms who started study treatment","reportingStatus":"POSTED","timeFrame":"Analysis occured after all patients have been on study for 2 years. Maximum follow-up at time of analysis was 8.5 years.","title":"Phase II: Overall Survival Rate at 2 Years (Including Phase I Patients at Same Dose)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}